Bibliography
- Puolakka K, Kautiainen H, Möttönen T, et al. and FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41
- Clowse MEB, Magder LS, Witter F, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21
- Landewé RB, Boers M, Verhoven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56
- Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81
- Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76
- Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in early weeks of pregnancy. Teratology 1993;47:533-9
- Schröder H, Fogh K. Methotrexate and its polyglutamate derivates in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1988;21:145-9
- Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-5
- Østensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000;27:1872-5
- Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92
- Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997;40:971-3
- Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J Rheumatol 2003;30:241-6
- Lewden B, Vial T, Elefant E, et al. Low dose weekly methotrexate in the first trimester of pregnancy: Results of a French collaborative study. J Rheumatol 2004;31:2360-5
- Østensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007;34:1266-9
- Rustin GJS, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J 1984;288:103-6
- De Santis M, Straface G, Cavaliere A et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005;64:1096-7
- Chambers CD, Johnson DL, Macaraeg GR, Jones KL. Pregnancy outcome following early gestational exposure to leflunomide: the OTIS Rheumatoid arthritis in pregnancy study (abstract). Pharmacoepidemiol Drug Saf 2004;13:S252
- Scarrazini L. Pregnancy exposure to leflunomide. Postmarketing data. Presented at the advisory board meeting: Arava and pregnancy, November 29-30th, 2007, Paris
- Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy (letter). Rheumatology 2007;46:1506
- Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008;2008:271363
- Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001;19:3439-40
- Decker M, Rothermundt C, Holländer G, et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006;7:693-694
- Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006;91:1426-7
- Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Europ J Haematol 2004;72:292-5
- Scully M, Starke R, Lee R, et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006;17:459-63
- Ojeda-Uribe M, Gilliot C, Jung G, et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26:252-5
- Scott JR. Fetal growth retardation associated with maternal administration of immunosuppressives. Am J Obstet Gynecol 1977;128:668-76
- Reinisch JM, Simon NG. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-8
- Østensen M, Fuhrer L, Mathieu R, et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004;63:1212-7
- de Man YA, Dolhain RJ, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;(59):1241-8
- Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-23
- Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007;197:585e1-585e7
- Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998;58:2-5
- Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Pal Craniofacial J 2003;40:624-8
- Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92
- Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002;46:1123-4
- Hart CN, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964;80:407-12
- Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-8
- Buchanan NMM, Toubi E, Khamashta KE, et al. Hydoxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996;55:486-8
- Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11
- Clowse MEB, Magder L, Witter F, Petri M. Hydoxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7
- Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001;(358):813-4
- Norgard B, Czeizel AE, Rockenbauer M, et al. Population based case control study of the safety of sulphasalazine used during pregnancy. Aliment Pharmacol Ther 2001;15:483-6
- Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterol 1981;80:72-6
- Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980;21:469-74
- Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1993;18:735-42
- Norgard B, Pedersen L, Christensen LA, Sörensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol 2007;102:1406-13
- Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14
- Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorect Dis 1997;12:220-4
- Bokström H, Holst RM, Hafström O, et al. Fetal haemolytic anemia associated with maternal sulfasalazine therapy during pregnancy. Acta Obstet Gynaecol Scand 2006;85:118-21
- Levi S, Libermann M, Levi AJ, et al. Reversible congenital neutropenia associated with maternal sulphasalazine therapy (letter). Eur J Pediat 1988;148:174-5
- Polifka JE, Friedman JM. Teratogen update: Azathioprine and 6-Mercaptopurine. Teratology 2002;65:240-61
- Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth def Res (Part A) 2007;79:696-701
- Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985;92:233-9
- Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. In: Cecka and Terasaki, Editors. Clin Trans 2004;103-14
- Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 1997;29:2480
- Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051-5
- Shaheen FAM, AI-Sulaiman MH, AI-Khader AA. Long-term nephrotoxicity after exposure to CsA in utero. Transplantation 1993;56:224-5
- Vasiliauskas EA, Church JA, Silverman N, et al. Evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8
- Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Dig Dis Week 2007;Abstract 959
- Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving Infliximab for the treatment of Crohn's Disease and Rheumatoid Arthritis. Am J Gastroenterol 2004;99:2385-92
- Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{alpha} therapy. Rheumatology 2006;46:695-8
- Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890
- Johnson DL, Jones KL Chambers CD. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Ann Rheum Dis 2008;67 (Suppl II): 303
- Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8
- Hyrich K, Symmons D, Watson K, Silman A. Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum 2006;54:2701-2
- Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006;8:215
- Carter JD, Valeriano J, Vasey FB, et al. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship? J Rheumatol 2006;33:1014-7
- Carter JD, Ladhani A, Ricca L, et al. A safety assessment of TNF Antagonists during pregnancy: a review of the FDA database. J Rheumatol 2008,doi:10.3899/jrheum.080545
- Østensen M. Are TNF inhibitors safe in pregnancy? Nature Rev Rheumatol 2009;5:184-5
- Ofori B, Oraichi D, Blais L, et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79
- Cleves MA, Savell VH Jr, Raj S, et al. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2004;70:107-13
- Kozer E, Shekoufeh N, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. Am J Obstet Gynecol 2002;187:1623-30
- Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton(MA): Littleton Publishing Sciences Group, 1977;286-95
- Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 6th edition. Lippincott Williams&Wilkins: Philadelphia, 2002
- Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 2001;322:266-70
- Momma K, Takeuchi H. Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins 1983;26:631-43
- Paladini D, Marasini M, Volpe P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet Gynecol 2005;25:357-61
- Stika CS, Gross GA, Leguizamon G, et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol 2002;187:653-60
- Alano MA, Ngougmna E, Ostrea EM, Jr KONDURI. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-3
- Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989;160:1525-31
- van der Heijden B, Gubler MC. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1995;9:675
- Nelson JL, Østensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:195-212
- Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994;37:808-813
- Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate in human milk. Am J Obstet Gynecol 1972;112:978-80
- Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993;53:324-8
- Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr 1985;106:1008-11
- Østensen M, Motta M. Review on antirheumatic drugs that can safely be used during nursing. Nature Clin Practice Rheumatol 2007;3:400-6
- Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86-9
- Jarnerot G, Into-Malberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979;14:869-71
- Gardiner SJ, Gearry RB, Roberst RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. BrJ Clin Pharmacol 2006;62:453-6
- Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008;28:1209-13
- Nyberg G, Haljamae U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation 1998;(65):253-5
- Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation 2003;(75):2144-6
- Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008;14:3085-7
- Østensen M, Eigenmann GO. Etanercept in breast milk (Letter). J Rheumatol 2004;31:1017
- Østensen M, Khamashta M, Lockshin M, et al. Antirheumatic drugs and reproduction. Arthritis Res Ther 2006;8:209
- Motta M, Tincani A, Meroni PL, Cimaz R. Follow-up of children exposed ante-natally to immunosuppressive drugs. Rheumatology (Oxford) 2008;47 Suppl 3:iii32-4
- Biggioggero M, Borghi MO, Gerosa M, et al. Immune function in children born to mothers with autoimmune diseases and exposed /in utero to immunosuppressants. Lupus 2007;16:651-6